Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 2/20 | 0.43 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.43 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.43 |
| ▸ | KDM1A | O60341 | 2/20 | 0.42 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.42 |
| ▸ | LTB4R2 | Q9NPC1 | 2/20 | 0.41 |
| ▸ | KCNQ4 | P56696 | 3/20 | 0.39 |
| ▸ | KCNQ5 | Q9NR82 | 3/20 | 0.39 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.39 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.39 |
| ▸ | BCL2A1 | Q16548 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.38 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.38 |
| ▸ | CNR2 | P34972 | 2/20 | 0.38 |
| ▸ | CNR1 | P21554 | 1/20 | 0.38 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3064159 | 0.88 | CHRM1 (0.42) | CHRM1CHRM3CHRM2KDM1AHDAC8 | |
| SCHEMBL3063855 | 0.86 | RIPK1 (0.43) | CHRM1CHRM3CHRM2LTB4R2RIPK1 | |
| SCHEMBL3822517 | 0.86 | LTB4R2 (0.46) | CHRM1CHRM3CHRM2LTB4R2BCL2A1 | |
| SCHEMBL3823174 | 0.84 | AAK1 (0.38) | CHRM1CHRM3CHRM2KDM1AHDAC8 | |
| SCHEMBL3058780 | 0.81 | CHRM1 (0.44) | CHRM1CHRM3CHRM2KDM1AHDAC8 | |
| SCHEMBL18721166 | 0.81 | KCNQ4 (0.43) | CHRM1CHRM3CHRM2KDM1AHDAC8 | |
| SCHEMBL3063916 | 0.81 | KCNQ4 (0.43) | CHRM1CHRM3CHRM2KDM1AHDAC8 | |
| SCHEMBL18721167 | 0.77 | NR1D1 (0.47) | — | |
| SCHEMBL3065942 | 0.76 | CACNA1H (0.46) | HDAC8HDAC6LTB4R2KCNQ4KCNQ5 | |
| SCHEMBL27527605 | 0.75 | TACR1 (0.40) | KMT2AHRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100267697-A1 | ION CHANNEL MODULATORS | WYETH (US) | 2010-10-21 | — | — | US | disclosed |
| US-20100267697-A1 | ION CHANNEL MODULATORS | WYETH (US) | 2010-10-21 | — | — | US | disclosed |
| EP-2099754-A1 | ION CHANNEL MODULATORS | Wyeth a Corporation of the State of Delaware (US) | 2009-09-16 | — | — | EP | disclosed |
| EP-2097379-A1 | CARBOXAMIDE DERIVATIVES AS ION CHANNEL MODULATORS | Wyeth a Corporation of the State of Delaware (US) | 2009-09-09 | — | — | EP | disclosed |
| EP-2091917-A1 | ION CHANNEL MODULATORS | Wyeth a Corporation of the State of Delaware (US) | 2009-08-26 | — | — | EP | disclosed |
| WO-2008073936-A1 | CARBOXAMIDE DERIVATIVES AS ION CHANNEL MODULATORS | WYETH (US) | 2008-06-19 | — | — | WO | disclosed |
| WO-2008073936-A1 | CARBOXAMIDE DERIVATIVES AS ION CHANNEL MODULATORS | WYETH (US) | 2008-06-19 | — | — | WO | disclosed |
| WO-2008073929-A1 | ION CHANNEL MODULATORS | WYETH (US) | 2008-06-19 | — | — | WO | disclosed |
| WO-2008073461-A2 | ION CHANNEL MODULATORS | WYETH (US) | 2008-06-19 | — | — | WO | disclosed |
| WO-2008073934-A1 | ION CHANNEL MODULATORS | WYETH (US) | 2008-06-19 | — | — | WO | disclosed |
| WO-2008073929-A1 | ION CHANNEL MODULATORS | WYETH (US) | 2008-06-19 | — | — | WO | disclosed |
| WO-2008073461-A2 | ION CHANNEL MODULATORS | WYETH (US) | 2008-06-19 | — | — | WO | disclosed |
| WO-2008073934-A1 | ION CHANNEL MODULATORS | WYETH (US) | 2008-06-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267697-A1 | ION CHANNEL MODULATORS | CACNA1E, CACNA1A, CACNA1S | CHRM1 215/4885CHRM3 217/4885CHRM2 223/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.